BioCentury | Aug 25, 2003
Finance

Aging the rally

...in stages, and tiers move independently," said Jonas Alsenas, manager of ING Barings Furman Selz's Crestwood Capital...
BioCentury | Aug 11, 2003
Finance

Ebb & Flow

..."all depends on the next manufacturing number," said Alsenas, manager for ING Barings Furman Selz's Crestwood Capital...
BioCentury | Jul 8, 2002
Finance

Ebb & Flow

...the Alkermes news was just chilling," said Jonas Alsenas, manager for ING Barings Furman Selz's Crestwood Capital...
BioCentury | May 13, 2002
Strategy

Pharma's future

...expiration date (see BioCentury, June 4, 2001). Jonas Alsenas, manager for ING Barings Furman Selz's Crestwood Capital...
BioCentury | May 13, 2002
Strategy

Rebasing pharma's growth

...single digit growth, and that could provide some enthusiasm" (see "Delayed Gratification"). Jonas Alsenas of Crestwood Capital...
BioCentury | Apr 1, 2002
Finance

1Q Financial Markets Review: Hoping for backloading

...that began on Sept. 30, 1999. Finally, Jonas Alsenas, manager of ING Barings Furman Selz's Crestwood Capital...
BioCentury | Jul 2, 2001
Finance

2Q Financial Markets Review: Identifying momentum

...the five- and ten-fold return," Murray said. Jonas Alsenas, manager for ING Barings Furman Selz's Crestwood Capital...
BioCentury | Apr 23, 2001
Finance

Can't earn no respect

...from a price-to-earnings growth (PEG) perspective, too. Jonas Alsenas, manager for ING Barings Furman Selz's Crestwood Capital...
BioCentury | Jul 3, 2000
Finance

The White House effect

...his sellside position at ING Barings to become portfolio manager for the firm's $500 million Crestwood Capital...
BioCentury | May 8, 2000
Financial News

Athersys raises $47.5 million

...Cleveland, Ohio), which is developing RAGE gene expression technology, included Invesco Funds; Van Wagoner Funds; Crestwood Capital...
Items per page:
1 - 10 of 10
BioCentury | Aug 25, 2003
Finance

Aging the rally

...in stages, and tiers move independently," said Jonas Alsenas, manager of ING Barings Furman Selz's Crestwood Capital...
BioCentury | Aug 11, 2003
Finance

Ebb & Flow

..."all depends on the next manufacturing number," said Alsenas, manager for ING Barings Furman Selz's Crestwood Capital...
BioCentury | Jul 8, 2002
Finance

Ebb & Flow

...the Alkermes news was just chilling," said Jonas Alsenas, manager for ING Barings Furman Selz's Crestwood Capital...
BioCentury | May 13, 2002
Strategy

Pharma's future

...expiration date (see BioCentury, June 4, 2001). Jonas Alsenas, manager for ING Barings Furman Selz's Crestwood Capital...
BioCentury | May 13, 2002
Strategy

Rebasing pharma's growth

...single digit growth, and that could provide some enthusiasm" (see "Delayed Gratification"). Jonas Alsenas of Crestwood Capital...
BioCentury | Apr 1, 2002
Finance

1Q Financial Markets Review: Hoping for backloading

...that began on Sept. 30, 1999. Finally, Jonas Alsenas, manager of ING Barings Furman Selz's Crestwood Capital...
BioCentury | Jul 2, 2001
Finance

2Q Financial Markets Review: Identifying momentum

...the five- and ten-fold return," Murray said. Jonas Alsenas, manager for ING Barings Furman Selz's Crestwood Capital...
BioCentury | Apr 23, 2001
Finance

Can't earn no respect

...from a price-to-earnings growth (PEG) perspective, too. Jonas Alsenas, manager for ING Barings Furman Selz's Crestwood Capital...
BioCentury | Jul 3, 2000
Finance

The White House effect

...his sellside position at ING Barings to become portfolio manager for the firm's $500 million Crestwood Capital...
BioCentury | May 8, 2000
Financial News

Athersys raises $47.5 million

...Cleveland, Ohio), which is developing RAGE gene expression technology, included Invesco Funds; Van Wagoner Funds; Crestwood Capital...
Items per page:
1 - 10 of 10